+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IL-12 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
IL-12 Receptor Antagonist Market - Global Forecast 2026-2032- Product Image
Sale

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6135098
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IL-12 Receptor Antagonist Market is projected to reach USD 314.22 Million in 2026. It is expected to continue growing at a CAGR of 8.94%, reaching USD 524.84 Million by 2032.

IL-12 Receptor Antagonists: Executive Overview

IL-12 receptor antagonists are an emerging class of immunomodulatory therapies designed to interrupt signaling associated with interleukin-12 activity. Their relevance is rooted in the role of IL-12 in T-cell and natural-killer-cell activation, interferon-gamma production, and inflammatory immune responses. Development activity is shaped by the need to balance meaningful immune modulation with infection risk, administration burden, and evidence requirements across immune-mediated diseases.

From Broad Immunosuppression to Targeted Cytokine Modulation

The therapeutic landscape is shifting toward more selective cytokine pathway intervention, biomarker-informed patient selection, and treatment strategies that aim to preserve protective immunity. For IL-12 receptor antagonists, this creates opportunities to differentiate through pathway specificity, dosing convenience, durable response, and positioning in patients who have inadequate responses or intolerance to established biologic approaches. Regulatory expectations increasingly emphasize clinically meaningful outcomes, safety characterization, and evidence across diverse patient populations.

Artificial Intelligence Accelerates Discovery, Development, and Care Pathways

Artificial intelligence can influence the field by identifying immune-response patterns, prioritizing therapeutic targets, optimizing antibody or protein design, and improving the interpretation of complex clinical data. In development programs, machine-learning methods may support trial-enrollment feasibility, endpoint analysis, safety-signal detection, and identification of response subgroups. Adoption should remain governed by data quality, explainability, privacy safeguards, prospective validation, and clear clinical accountability rather than by algorithmic performance alone.

Regional Insights: Regulation, Access, and Translational Capacity Differ

North America combines strong biomedical research capacity with sophisticated biologic-development infrastructure and demanding evidence standards. Europe emphasizes coordinated regulatory science, health-technology assessment, and comparative clinical value, while the European Union adds cross-border considerations for trial execution and access. Asia-Pacific offers expanding clinical, manufacturing, and translational capabilities, particularly across Japan, China, South Korea, Australia, and India. Latin America presents opportunities linked to rising specialty-care capacity but requires attention to reimbursement variation and trial logistics. The Middle East is shaped by concentrated healthcare investment and varying national procurement systems, while Africa requires strategies adapted to uneven specialist access, diagnostic infrastructure, and infectious-disease considerations.

Group Insights: Trade Blocs and Alliances Shape Development Strategy

ASEAN markets require country-sensitive approaches because regulatory pathways, reimbursement systems, and specialist capacity differ across members. BRICS economies offer substantial scientific and clinical diversity, alongside varied intellectual-property, procurement, and evidence environments. The European Union supports collaborative research and coordinated regulatory engagement, although national reimbursement decisions remain important. G7 members generally provide mature clinical infrastructure and stringent evidence expectations. GCC countries can offer centralized procurement opportunities and well-resourced specialty-care hubs. NATO members span diverse healthcare systems, making alliance membership less determinative than national regulation, funding, and clinical-network readiness.

Country Insights: Local Evidence and Access Conditions Remain Decisive

Australia supports advanced clinical research and regulated biologic access, while Brazil and Mexico require navigation of diverse public and private healthcare channels. Canada combines strong research institutions with centralized and provincial access considerations. China is expanding biomedical capabilities under a distinct regulatory and reimbursement environment; India offers broad clinical depth but highly variable access conditions. Japan and South Korea maintain advanced specialty-care systems with country-specific evidence expectations. France, Germany, Italy, Spain, and the United Kingdom require alignment with national and regional assessment processes. Russia presents a distinct regulatory and operating context. In the United States, differentiated clinical evidence, payer engagement, and physician adoption are central to uptake.

Priorities for Leaders: Build Evidence, Resilience, and Patient Relevance

Industry leaders should define a focused clinical use case, establish translational biomarkers early, and design trials that demonstrate both efficacy and clinically relevant safety. Development plans should incorporate diverse geographies, pragmatic evidence generation, and clear differentiation from existing immune-modulating options. Manufacturing and supply strategies should address biologic complexity, quality consistency, cold-chain requirements, and geopolitical resilience. Organizations should also formalize responsible-AI governance, engage regulators and health-technology assessors early, and develop access plans that reflect country-level reimbursement and diagnostic realities.

Methodology: Evidence Triangulation Across Science, Regulation, and Access

This executive summary uses a structured synthesis of publicly verifiable scientific, clinical, regulatory, and healthcare-system evidence relevant to IL-12 receptor antagonists. The assessment considers biological rationale, therapeutic-development patterns, safety and evidence requirements, regional operating conditions, and group- and country-level access factors. Interpretations are framed qualitatively and avoid unsupported market estimates, market shares, forecasts, or company-specific claims. Findings should be refreshed as clinical readouts, regulatory decisions, treatment guidelines, and reimbursement policies evolve.

Conclusion: Selective Immunomodulation Requires Precise Execution

IL-12 receptor antagonists sit within a broader movement toward targeted immune-pathway control. Their prospects depend on demonstrating a clear therapeutic role, maintaining an acceptable safety profile, and translating mechanistic selectivity into outcomes valued by patients, clinicians, regulators, and payers. Success will require disciplined evidence generation, regionally informed access planning, responsible use of artificial intelligence, and sustained attention to manufacturing and healthcare-system readiness.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IL-12 Receptor Antagonist Market, by Indication
7.1. Introduction
7.2. Crohn Disease
7.3. Psoriasis
7.4. Psoriatic Arthritis
7.5. Ulcerative Colitis
8. IL-12 Receptor Antagonist Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous Infusion
8.3. Subcutaneous Injection
8.3.1. Auto Injector
8.3.2. Prefilled Syringe
9. IL-12 Receptor Antagonist Market, by Form
9.1. Introduction
9.2. Auto Injector
9.3. Lyophilized Powder
9.4. Prefilled Syringe
9.5. Solution
10. IL-12 Receptor Antagonist Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. IL-12 Receptor Antagonist Market, by Dosage Strength
11.1. Introduction
11.2. High Dose
11.3. Low Dose
11.4. Medium Dose
12. IL-12 Receptor Antagonist Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Home Care
12.4. Hospitals
12.5. Specialty Clinics
13. IL-12 Receptor Antagonist Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. IL-12 Receptor Antagonist Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. IL-12 Receptor Antagonist Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. IL-12 Receptor Antagonist Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. AI Therapeutics, Inc.
18.3. Akeso, Inc.
18.4. Alaunos Therapeutics, Inc.
18.5. Alvotech hf.
18.6. Amgen Inc.
18.7. AstraZeneca PLC
18.8. BioInvent International AB
18.9. Boehringer Ingelheim International GmbH
18.10. Cipla Limited
18.11. ESSA Pharma Inc.
18.12. Fuji Pharma Co., Ltd.
18.13. Janssen Pharmaceutica NV
18.14. Madrigal Pharmaceuticals, Inc.
18.15. Pfizer Inc.
18.16. Samsung Bioepis Co., Ltd.
18.17. Teva Pharmaceutical Industries Ltd.
18.18. Tourmaline Bio, Inc.
18.19. VBL Therapeutics Ltd.
18.20. Ventyx Biosciences, Inc.
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global IL-12 Receptor Antagonist Market, Years Considered for the Study
FIGURE 2. Global IL-12 Receptor Antagonist Market, Research Design
FIGURE 3. Global IL-12 Receptor Antagonist Market, Research Framework
FIGURE 4. Global IL-12 Receptor Antagonist Market, Data Triangulation
FIGURE 5. Global IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
FIGURE 6. Global IL-12 Receptor Antagonist Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global IL-12 Receptor Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global IL-12 Receptor Antagonist Market Size, by Form, 2025 vs 2032 (%)
FIGURE 11. Global IL-12 Receptor Antagonist Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 15. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global IL-12 Receptor Antagonist Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global IL-12 Receptor Antagonist Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 19. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global IL-12 Receptor Antagonist Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global IL-12 Receptor Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global IL-12 Receptor Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global IL-12 Receptor Antagonist Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global IL-12 Receptor Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global IL-12 Receptor Antagonist Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global IL-12 Receptor Antagonist Market Segmentation & Coverage
TABLE 2. Global IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 3. Global IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Crohn Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Crohn Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Crohn Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 17. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Auto Injector Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Auto Injector Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Auto Injector Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 30. Global Auto Injector Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Auto Injector Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Auto Injector Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Solution Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Solution Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Solution Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 43. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 53. Global High Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global High Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global High Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Low Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Low Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Low Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Medium Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Medium Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Medium Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. North America IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. North America IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. North America IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. North America IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 99. North America IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 100. North America IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 101. North America IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 102. North America IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. North America IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Latin America IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Latin America IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 106. Latin America IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 107. Latin America IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 108. Latin America IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 109. Latin America IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 110. Latin America IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 111. Latin America IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. Latin America IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Europe IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Europe IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. Europe IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 116. Europe IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 117. Europe IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 118. Europe IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. Europe IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 120. Europe IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 121. Europe IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Middle East IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Middle East IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 124. Middle East IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 125. Middle East IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 126. Middle East IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 127. Middle East IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 128. Middle East IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 129. Middle East IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Middle East IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 131. Africa IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Africa IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 133. Africa IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. Africa IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 135. Africa IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 136. Africa IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 137. Africa IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 138. Africa IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. Africa IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Global IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. ASEAN IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. ASEAN IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 143. ASEAN IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 144. ASEAN IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 145. ASEAN IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 146. ASEAN IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. ASEAN IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 148. ASEAN IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 149. ASEAN IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. GCC IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. GCC IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 152. GCC IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 153. GCC IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 154. GCC IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 155. GCC IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 156. GCC IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 157. GCC IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. GCC IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. European Union IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 160. European Union IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 161. European Union IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 162. European Union IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 163. European Union IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 164. European Union IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 165. European Union IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 166. European Union IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. European Union IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. BRICS IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 169. BRICS IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 170. BRICS IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 171. BRICS IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 172. BRICS IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 173. BRICS IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. BRICS IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 175. BRICS IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. BRICS IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. G7 IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. G7 IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. G7 IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 180. G7 IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 181. G7 IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 182. G7 IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 183. G7 IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 184. G7 IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. G7 IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. NATO IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 187. NATO IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. NATO IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 189. NATO IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 190. NATO IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 191. NATO IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 192. NATO IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 193. NATO IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. NATO IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 195. Global IL-12 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 196. United States IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 197. United States IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 198. United States IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. United States IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 200. United States IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 201. United States IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 202. United States IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 203. United States IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 204. United States IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Canada IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 206. Canada IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. Canada IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 208. Canada IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 209. Canada IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 210. Canada IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Canada IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 212. Canada IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. Canada IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. Mexico IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 215. Mexico IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 216. Mexico IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 217. Mexico IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 218. Mexico IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 219. Mexico IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 220. Mexico IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 221. Mexico IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. Mexico IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. Brazil IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 224. Brazil IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 225. Brazil IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. Brazil IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 227. Brazil IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 228. Brazil IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 229. Brazil IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 230. Brazil IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 231. Brazil IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. United Kingdom IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 233. United Kingdom IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. United Kingdom IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 235. United Kingdom IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 236. United Kingdom IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 237. United Kingdom IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. United Kingdom IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 239. United Kingdom IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. United Kingdom IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. Germany IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 242. Germany IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. Germany IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. Germany IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 245. Germany IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 246. Germany IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 247. Germany IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 248. Germany IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. Germany IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. France IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 251. France IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 252. France IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 253. France IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 254. France IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 255. France IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 256. France IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 257. France IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 258. France IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Russia IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 260. Russia IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 261. Russia IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 262. Russia IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 263. Russia IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 264. Russia IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 265. Russia IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 266. Russia IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Russia IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Italy IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 269. Italy IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 270. Italy IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. Italy IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 272. Italy IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 273. Italy IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 274. Italy IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 275. Italy IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 276. Italy IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. Spain IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 278. Spain IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. Spain IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Spain IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 281. Spain IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 282. Spain IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 283. Spain IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 284. Spain IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 285. Spain IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. China IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 287. China IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 288. China IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 289. China IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 290. China IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 291. China IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 292. China IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 293. China IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 294. China IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. India IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 296. India IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 297. India IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 298. India IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 299. India IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 300. India IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 301. India IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 302. India IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. India IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Japan IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 305. Japan IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 306. Japan IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 307. Japan IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 308. Japan IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 309. Japan IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 310. Japan IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 311. Japan IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. Japan IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. Australia IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 314. Australia IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 315. Australia IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 316. Australia IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 317. Australia IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 318. Australia IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 319. Australia IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 320. Australia IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 321. Australia IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 322. South Korea IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
TABLE 323. South Korea IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
TABLE 324. South Korea IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 325. South Korea IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
TABLE 326. South Korea IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
TABLE 327. South Korea IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 328. South Korea IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 329. South Korea IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
TABLE 330. South Korea IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 331. Global IL-12 Receptor Antagonist Market Share, by Key Player, 2025
TABLE 332. Global IL-12 Receptor Antagonist Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • AI Therapeutics, Inc.
  • Akeso, Inc.
  • Alaunos Therapeutics, Inc.
  • Alvotech hf.
  • Amgen Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • ESSA Pharma Inc.
  • Fuji Pharma Co., Ltd.
  • Janssen Pharmaceutica NV
  • Madrigal Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tourmaline Bio, Inc.
  • VBL Therapeutics Ltd.
  • Ventyx Biosciences, Inc.

Related Topics

Related Reports

IL-1 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-1 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
IL-23 Receptor Antagonist Market - Global Forecast 2026-2032 - Product Image

IL-23 Receptor Antagonist Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors - Product Image

Pipeline of Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors

  • Report
  • Global
From
Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Diffuse cutaneous systemic sclerosis (dcSSc) - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Diffuse cutaneous systemic sclerosis (dcSSc) - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.